BioSpace News Archive

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute (NCI), part of the National Institutes of Health.

Humacyte, Inc. (Nasdaq: HUMA), today announced that six-month outcomes from a preclinical study of a small diameter Human Acellular Vessel™ (HAVTM) in coronary artery bypass grafting will be presented at the Basic Cardiovascular Sciences (BCVS) Scientific Sessions taking place in Chicago, IL July 25-28, 2022.

Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will issue a press release on the Company’s second quarter 2022 financial results on Tuesday, August 2, 2022.

Creative Bio-Peptides, Inc, today announced the publication of findings from a preclinical study showing that treatment with the multi-chemokine receptor antagonist oral peptide RAP-103 substantially reduced heroin self-administration and motivation to consume heroin.

Agiliti Inc. announced that the company will release its second quarter results after the market close on Tuesday, August 9, 2022, to be followed by a conference call at 5 p.m. Eastern Time on the same day.

Enovis Launches ARVIS ® , Only Augmented Reality Surgical Guidance System Designed Specifically to Improve Both Total Hip and Knee Replacement Surgery.

Cardurion Pharmaceuticals, Inc. today announced it has opened multiple sites and commenced dosing patients in a Phase 2 clinical trial of CRD-740, a phosphodiesterase-9 (“PDE9”) inhibitor for the treatment of heart failure.

Celsion Corporation (NASDAQ: CLSN ), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of (i) inducement stock options (the “Inducement Option Grants”) to purchase a total of 177,000 shares of common stock, and (ii) restricted stock grants.

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its third quarter fiscal 2022 conference call on Wednesday, July 27, at 7:30 a.m. CT (8:30 a.m. ET).

Avantor, Inc. has appointed veteran strategy and M&A executive, Kitty Sahin, to the newly created role of EVP, Strategy and Corporate Development, effective immediately.